NEC’s Artificial Intelligence (AI) Supports Doctors to Determine If Colorectal Lesions Are Potentially Neoplastic
CE marking-compliant software; soon available in Europe
Colorectal cancer originates from precancerous lesions (colorectal neoplastic polyps) and it is possible to suppress its progression by detecting and removing lesions at an early stage during endoscopy procedures. It is, however, sometimes difficult for endoscopists to visually distinguish between neoplastic and non-neoplastic lesions during endoscopy examinations, resulting in unnecessary biopsies and removal of non-neoplastic lesions, thereby causing additional stress and discomfort to patients. Colorectal cancer is said to be the second-largest cancer (*2) in the European region, and the latest version of WISE VISION® Endoscopy, which launches first in Europe, promises to help doctors address this challenging issue.
To improve the chances of identifying if colorectal lesions are possibly neoplastic, and so to help endoscopists in their decision process, NEC developed a new technology where the learning power of AI is used to combine information of endoscopy images and data from the findings of expert physicians. Specifically, the technology analyzes still images of lesions taken with endoscopy devices, and if the AI determines that a colorectal lesion is likely to be neoplastic a “High possibility” notification message is displayed.
For More Information
URL: https://www.nec.com/en/press/202107/global_20210714_03.html
Notes:
(*1) “WISE VISION” is a registered trademark of NEC Corporation in the United States of America, the European Union and the United Kingdom.
(*2) According to United European Gastroenterology
https://ueg.eu/p/78#
View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005377/en/
Website: http://www.nec.com
Contact
NEC Corporation
Joseph Jasper